ABIOMED Aktie
Personal
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 1 143 | 1 371 | 1 536 | 1 725 | 2 003 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,52 | 0,56 | 0,55 | 0,49 | 0,52 |
Bilanz (in Mio. USD) - Aktiva
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 494 | 677 | 636 | 788 | 976 |
| Summe Anlagevermögen | 292 | 377 | 581 | 706 | 697 |
| Summe Aktiva | 786 | 1 054 | 1 216 | 1 494 | 1 673 |
Bilanz (in Mio. USD) - Passiva
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 97 | 117 | 151 | 165 | 170 |
| Summe Eigenkapital | 690 | 937 | 1 065 | 1 330 | 1 503 |
| Summe Passiva | 786 | 1 054 | 1 216 | 1 494 | 1 673 |
Adresse
| 22 Cherry Hill Drive, 01923 Danvers | |
| Telefon | +1 (978) 646-1400 |
| Internet | http://www.abiomed.com |
Management
|
Adrienne Carney
Head-Human Resources |
|
Andrew J. Greenfield
President |
|
Charles A. Simonton
Chief Medical Officer & Executive Vice President |
|
David Fortunati
Director |
|
Jeffrey Blizard
Head-Surgical Sales |
|
Laxmi N. Peri
Senior Vice President-Engineering |
|
Poornima Sood
Vice President-Clinical & Regulatory Affairs |
|
Susan Morano
Director |
|
Thorsten Sieß
Chief Technology Officer, Managing Director & EVP |
|
Todd Tetreault
Chief Financial Officer |
|
Vincent Sommella
Director |
|
Will Danzinger
Chief Operating Officer |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
